Summary by Moomoo AI
Hangzhou Qiming Medical Equipment Co., Ltd. ("Qiming Medical") announces its unaudited interim performance for the six months ended June 30, 2024. During the reporting period, the company's revenue was RMB 230,720,000, a decrease of 9.7% compared to the same period last year; gross profit was RMB 181,760,000, a decrease of 9.7% year-on-year. The loss during the period was RMB 208,825,000, a decrease of 43.0% compared to RMB 366,215,000 in the same period last year. The loss attributable to the owners of the parent company was RMB 206,487,000, a decrease of 41.0%. The commercial profit under non-international financial reporting standards was RMB 34,131,000, an increase of 85%; non-international financial reporting standard EBITDA was RMB (145,286,000), an improvement of 48.7%. The company continues to focus on the field of structural heart disease, actively responding to internal and external challenges, pursuing market share and commercial profitability, and adhering to the "profitization" strategy. The company's shares have been suspended from trading on the Hong Kong Stock Exchange since November 23, 2023.
